| Publisher's note: FierceBiotech will not be publishing Thursday, November 24, or Friday, November 25, in celebration of Thanksgiving. Keep an eye out Friday, however, for our annual "Best Of" edition highlighting the most-read stories of the year. Have a happy holiday, and as always, thank you for reading.
Top Stories Wednesday, November 23, 2016 For the second time this year Juno has seen its midstage CAR-T Rocket trial put on hold, although this time the biotech has limited its test on its own, after two patients suffered cerebral edema earlier this week, with one dead as of last night and the other “not expected to recover.” Wednesday, November 23, 2016 We know it’s a top priority for Congress, but a group of panelists speaking at an “emergency briefing” in the U.S. Senate this week hosted by an anti-FDA legal co have urged lawmakers to not “rush a closed-door negotiated version of the bill during the lame-duck session.” Wednesday, November 23, 2016 Allergan. M&A of an SME biotech. Millions of dollars involved, biobucks down the line. Seem familiar? Well, the co, still paving an independent path forward after not being subsumed by Pfizer in the spring, is at it again—this time buying out Chase Pharma in a $125 million deal. Wednesday, November 23, 2016 Orchard Therapeutics has secured a $20 million grant to trial its stem cell gene therapy in patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). The funding will enable Orchard to learn whether its lentiviral approach can offer patients an alternative to GlaxoSmithKline's Strimvelis. Wednesday, November 23, 2016 Galapagos and Gilead have dosed the first patient in a phase 3 Crohn’s disease trial of JAK1 inhibitor filgotinib. The initiation of the study sends the partners barreling toward pivotal data in an indication Gilead sees as a key component of its $2 billion deal with Galapagos. Tuesday, November 22, 2016 Intarcia Therapeutics has filed for FDA approval of its osmotic mini-pump type 2 diabetes treatment. The submission triggered a $100 million payment, giving Intarcia some of the cash it will need to take on Big Pharma in the fiercely competitive diabetes sector should it win approval. | | | Neurotrope has issued a note saying that while it is saddened by Lilly's amyloid Alzheimer's therapy failure, it believes its rival pipeline med bryostatin will still come through its tests. Release South Korean biotech Green Cross Corporation has been given a complete response letter from the FDA for its med IVIG-SN that is seeking to treat primary immunodeficiency diseases. Statement | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico Immunotherapy: Mapping the Future of Cancer Drug Discovery November 28, 2016 | Munich, Germany 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA | 